Tuesday, November 9, 2021
- 8:30AM-10:30AM
-
Abstract Number: 1632
Clinical Features and Colchicine Response in Patients with Undifferentiated Systemic Autoinflammatory Disease Carrying E148Q vs. Other MEFV Mutations
Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)- 8:30AM-10:30AM
-
Abstract Number: 1638
Clinical Manifestations of COVID-19 and Its Impact on Pediatric Patients with Rheumatic Disease
Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)- 8:30AM-10:30AM
-
Abstract Number: 1555
Clinical Outcomes of Coronavirus Disease-2019 (COVID-19) in Hospitalized Patients with Rheumatic and Musculoskeletal Diseases (RMD)
Infection-related Rheumatic Disease Poster (1530–1564)- 8:30AM-10:30AM
-
Abstract Number: 1710
Clinical Outcomes of MTX-Naïve RA Patients on Filgotinib Long-term Extension Trial Initially on FIL or MTX During Phase 3 Parent Trial
RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)- 8:30AM-10:30AM
-
Abstract Number: 1697
Clinical Outcomes up to Week 48 of Filgotinib Treatment in an Ongoing Long-term Extension Trial of RA Patients with Inadequate Response to MTX Initially Treated with Filgotinib or Adalimumab During the Phase 3 Parent Trial
RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)- 8:30AM-10:30AM
-
Abstract Number: 1696
Clinical Outcomes up to Week 48 of Ongoing Filgotinib RA Long-term Extension Trial of Biologic DMARD Inadequate Responders Initially on Filgotinib or Placebo in a Phase 3 Trial
RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)- 8:30AM-10:30AM
-
Abstract Number: 1516
Clinical Phenotypes and Treatment of Rheumatic Immune-Related Adverse Events from Checkpoint Inhibitors: A Retrospective Cohort of 112 Patients
Immunological Complications of Therapy Poster (1516–1529)- 8:30AM-10:30AM
-
Abstract Number: 1757
Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: A Case Series
SLE – Treatment Poster (1732–1772)- 8:30AM-10:30AM
-
Abstract Number: 1862
Clonal Hematopoiesis Across the Age Spectrum in Patients with Systemic Vasculitis
Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)- 8:30AM-10:30AM
-
Abstract Number: 1654
Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL
RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)- 8:30AM-10:30AM
-
Abstract Number: 1870
Comparative Study on Anti-TNF vs Tocilizumab for Treatment of Refractory Uveitic Cystoid Macular Edema Due to Behcet’s Disease: Multicenter Study of 49 Patients
Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)- 8:30AM-10:30AM
-
Abstract Number: 1773
Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from DISCOVER 1&2 and PSUMMIT Trials
Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)- 8:30AM-10:30AM
-
Abstract Number: 1802
Comparison of Axial and Peripheral Manifestations in Patients with Psoriatic Arthritis and Ankylosing Spondylitis in Upadacitinib Clinical Trials
Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)